PT-141 (Bremelanotide) Manufacturer Bridge Programs: How to Get Vyleesi Cheaper

What Is PT-141 and Why Does It Cost So Much?

Bremelanotide, sold under the brand name Vyleesi, is the only FDA-approved subcutaneous peptide for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin receptors (MC3R and MC4R) in the central nervous system rather than through vascular pathways, which sets it apart mechanistically from sildenafil-type drugs developed for men.

The FDA approved Vyleesi in June 2019 based on two Phase 3 trials, RECONNECT-1 and RECONNECT-2, which together enrolled 1,247 premenopausal women. Across both trials, women using bremelanotide reported statistically significant improvements in satisfying sexual events and reductions in distress compared with placebo.

Cost is the primary access barrier. A single auto-injector kit carries a list price in the range of $1,050 to $1,300 as of early 2026. Because most commercial insurance plans either exclude HSDD drugs entirely or impose high tiers, many women pay close to list price without intervention.

Why Insurance Coverage Is So Patchy

HSDD affects an estimated 10% of U.S. Women, yet insurance coverage for its treatment lags far behind coverage for comparable male sexual dysfunction drugs. A 2023 analysis published in the Journal of Women's Health found that fewer than 30% of large employer health plans covered any FDA-approved HSDD medication on formulary without prior authorization.

Palatin Technologies created manufacturer support programs specifically because so many commercial plans exclude the drug or place it at specialty tier.

The Vyleesi Manufacturer Savings Card Program

The Vyleesi savings card is the fastest, lowest-friction option for commercially insured women who do not qualify for Medicaid or government programs. Here is how it works in practice.

Eligibility

To use the savings card you must:

• Have a valid prescription from a licensed U.S. Clinician
• Have commercial health insurance (government insurance including Medicare, Medicaid, TRICARE, and VA benefits disqualifies you)
• Be a U.S. Resident
• Be at least 18 years old

Women on employer-sponsored plans, marketplace ACA plans, or individual commercial plans typically qualify.

What the Program Covers

The program structure as of 2026 allows eligible women to pay as little as $0 for their first fill, with the manufacturer covering the gap between your plan's copay and the actual cost up to an annual cap. Program limits and terms change frequently, so confirm the current annual maximum directly on the Vyleesi patient support site or by calling the program hotline before you fill your first prescription.

The annual benefit cap has historically been set at approximately $3,600, which translates to roughly three to four fully covered doses per year depending on your plan's negotiated price. Women who need more doses per year should combine the savings card with other strategies listed below.

How to Enroll

1. Obtain a prescription from your clinician (telehealth prescribers qualify).
2. Visit the official Vyleesi savings card enrollment page and register with your name, date of birth, and insurance information.
3. Download or print the card (or use the digital version at the pharmacy counter).
4. Present the card when you pick up or receive your prescription.

Enrollment takes under five minutes. You do not need prior authorization approval in hand before enrolling in the card program, though your pharmacy may still require it from your insurer.

Patient Assistance Program (PAP) for Uninsured or Underinsured Women

If you are uninsured or your income is below a certain threshold, you may qualify for the Vyleesi Patient Assistance Program, which provides the medication at no cost.

Eligibility Criteria

Specific income thresholds are based on federal poverty level guidelines and are revised annually. As a general reference point, programs of this type typically cover households earning up to 400% to 600% of the federal poverty level, though Palatin's current threshold should be confirmed directly through their program line.

Required documentation generally includes:

• Proof of income (most recent tax return or pay stubs)
• Proof of U.S. Residency
• A signed prescription from your clinician
• Confirmation that you do not have insurance or that your insurance does not cover the drug

Your clinician's office can submit the application on your behalf, which is often faster than self-submitting.

Processing Time

Allow four to six weeks for initial approval. Once approved, most PAP agreements run for 12 months before re-verification.

Compounded Bremelanotide: A Lower-Cost Alternative

Compounded bremelanotide from FDA-registered 503A compounding pharmacies is the most common pathway for women who want cost reduction without navigating insurance at all. Understanding the difference between branded Vyleesi and compounded PT-141 is clinically important.

Branded vs. Compounded: What Changes

| Feature | Vyleesi (branded) | Compounded PT-141 | |---|---|---| | FDA approval status | Approved (NDA 210557) | Not FDA-approved | | Manufacturer quality oversight | Yes (full GMP) | Variable; depends on pharmacy | | Typical cost per dose | $1,050-$1,300 list | $40-$150 depending on pharmacy and dose | | Dose form | 1.75 mg subcutaneous auto-injector | Variable (commonly 1-2 mg vials for reconstitution) | | Savings card eligible | Yes | No | | HSA/FSA eligible | Yes, with prescription | Yes, with prescription |

Compounded peptides are not interchangeable with the branded product from a regulatory standpoint. The FDA has noted that compounded peptides may not meet the same purity, sterility, and potency standards as approved drugs. At the same time, many women who cannot access or afford Vyleesi use compounded bremelanotide through telehealth platforms that operate compounding pharmacy partnerships.

If you pursue compounded bremelanotide, choose a pharmacy that holds USP 797 and USP 800 sterile compounding certifications and that provides a certificate of analysis for each batch.

Dose Differences to Know

The FDA-approved dose is 1.75 mg injected subcutaneously 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per 24-hour period. Compounding pharmacies sometimes offer doses starting at 1 mg for women who are sensitive to side effects, particularly nausea. There are no prospective published dose-finding studies in women comparing 1 mg versus 1.75 mg outcomes, which is an evidence gap you should discuss with your prescriber.

HSA and FSA Eligibility for PT-141

Yes. Bremelanotide, both branded Vyleesi and compounded PT-141, is eligible for purchase using Health Savings Account (HSA) or Flexible Spending Account (FSA) funds when you have a valid prescription from a licensed clinician.

The IRS defines qualified medical expenses to include prescription drugs, and bremelanotide meets this definition once prescribed. You do not need a Letter of Medical Necessity for a prescription drug, though some FSA administrators may request documentation, so keep a copy of your prescription on file.

Practical steps:

• Pay for your prescription using your HSA debit card at the pharmacy or through the telehealth platform's pharmacy partner.
• If you pay out-of-pocket first, submit a reimbursement claim with your receipt and prescription confirmation.
• For compounded PT-141, the compound must be prescribed (not purchased as a supplement or research chemical) to qualify as a legitimate FSA/HSA expense.

Using HSA dollars effectively reduces your after-tax cost by your marginal tax rate. For a woman in the 22% federal bracket, a $150 compounded dose costs approximately $117 in pre-tax terms.

Telehealth Platforms and Prescription Access

Telehealth prescribing has made PT-141 accessible to women in most U.S. States without in-person visits. Several women's health telehealth companies include bremelanotide in their sexual health formularies, often paired with a compounding pharmacy network.

What to evaluate when choosing a telehealth platform:

• Is the prescriber a licensed clinician (NP, PA, or MD) with women's health training?
• Does the platform use an accredited compounding pharmacy?
• Is a certificate of analysis available for each batch?
• Does the platform screen for contraindications, including cardiovascular risk and medication interactions?
• Is follow-up included or billed separately?

Platforms that bundle consultation, prescription, and compounded medication into a monthly subscription fee may offer the lowest total cost, but read the cancellation terms carefully.

Women's Physiology and What It Means for Your Experience

Bremelanotide's mechanism is central, not peripheral. It acts on hypothalamic melanocortin receptors to increase sexual motivation. Sex-specific physiological differences matter for how you experience both the drug's effects and its side effects.

Nausea: The Most Common Side Effect and Why Women May Be More Susceptible

In the RECONNECT trials, nausea occurred in approximately 40% of women using bremelanotide versus 1% with placebo. Women generally have slower gastric emptying than men, a difference amplified during the luteal phase of the menstrual cycle. If you notice nausea is worse in the week before your period, try dosing closer to 60 to 90 minutes before activity rather than the label's 45-minute window, and eat a light snack beforehand. This is empirical advice based on gastric motility physiology, not a controlled trial result.

Menstrual Cycle Timing

No published data specifically examine whether bremelanotide efficacy varies across the menstrual cycle. The RECONNECT trials did not stratify outcomes by cycle phase. Given that endogenous estrogen and progesterone influence melanocortin receptor sensitivity, cycle timing may matter, but direct evidence is absent. This is an evidence gap.

Blood Pressure Transient

Bremelanotide causes a transient increase in blood pressure, typically peaking within 12 minutes of injection and resolving within 12 hours. The prescribing information notes a mean maximum increase of approximately 6 mmHg systolic and 4 mmHg diastolic. Women with pre-existing hypertension or cardiovascular disease should not use this drug. Women with white-coat hypertension or anxiety-related blood pressure elevation should discuss baseline cardiovascular screening with their clinician before starting.

PCOS and Bremelanotide

Women with PCOS have elevated baseline androgens and altered hypothalamic-pituitary signaling. There are no published trials or case series specifically examining bremelanotide in women with PCOS. Clinically, HSDD and reduced sexual satisfaction are reported at higher rates in women with PCOS than in age-matched controls, which makes HSDD treatment relevant to this population. The evidence gap here is real, and you should tell your prescriber about your PCOS diagnosis before starting.

Life Stage Guide: Who This Is Right For (and Who It Is Not)

Reproductive Years (Premenopausal, Not Trying to Conceive)

This is the FDA-approved population. If you have acquired, generalized HSDD confirmed by a validated screening tool such as the Decreased Sexual Desire Screener (DSDS), you are the patient this drug was designed for. Use reliable contraception while on treatment (see pregnancy section below).

Trying to Conceive

Bremelanotide is contraindicated. Discontinue the drug before attempting conception. There are no reliable data on how quickly the drug clears to safe levels before a conception attempt; the prescribing information recommends stopping treatment before trying to conceive. Discuss timing with your reproductive endocrinologist or OB-GYN.

Postpartum and Lactating Women

Bremelanotide is not approved for postpartum or lactating women, and there are no published pharmacokinetic data on bremelanotide transfer into human breast milk. Until lactation transfer data exist, the drug should be avoided while breastfeeding. Low libido postpartum is overwhelmingly driven by hormonal shifts (low estrogen, low testosterone), sleep deprivation, and the physical demands of newborn care. A conversation with your OB-GYN or WHNP about the full picture is more appropriate than bremelanotide for this life stage.

Perimenopause

Bremelanotide is not FDA-approved for perimenopausal women, and perimenopausal women were not included in the RECONNECT trials. Off-label use is clinically plausible given that HSDD persists and worsens through perimenopause, but data are absent. The Menopause Society (NAMS) 2022 position statement on sexual health does not include bremelanotide in its recommendations for menopausal women, noting insufficient evidence in this group. If you are perimenopausal, discuss whether estrogen optimization or testosterone therapy may address the hormonal drivers before adding bremelanotide.

Postmenopause

Same evidence gap as perimenopause. Savings card and manufacturer programs explicitly exclude postmenopausal use from their covered indication, which means even if a clinician prescribes off-label, the savings card will not apply. Compounded bremelanotide with HSA/FSA payment remains a cost option for postmenopausal women whose clinicians support off-label use.

Pregnancy, Lactation, and Contraception: Required Reading

Bremelanotide is contraindicated in pregnancy. This is not a precautionary hedge. Animal reproduction studies showed fetal harm at doses producing exposures lower than those seen in humans at the therapeutic dose.

The FDA prescribing label assigns bremelanotide to the category of drugs with demonstrated fetal risk based on animal data, with no adequate and well-controlled studies in pregnant women. If you discover you are pregnant while using bremelanotide, stop the drug immediately and contact your OB-GYN.

Contraception Requirement

You must use effective contraception while using bremelanotide if pregnancy is a possibility. The label does not specify a required contraceptive method, so any reliably used hormonal method, IUD, or barrier method with consistent use is acceptable. Discuss your contraceptive plan with your clinician at the time of prescription.

Lactation

No human lactation data exist. Bremelanotide and its metabolite MT-II are lipophilic peptides, and some transfer into breast milk is likely, though the extent and infant dose are unknown. The conservative clinical recommendation is to avoid bremelanotide while breastfeeding. If a breastfeeding woman with severe HSDD and her clinician decide to proceed, pumping and discarding milk for at least 24 hours post-injection is a common harm-reduction approach, though this is not supported by pharmacokinetic data and represents extrapolation only.

Combining Cost Strategies: A Practical Decision Tree

Not every woman has the same insurance situation. Here is a framework for matching your situation to the best access pathway.

Step 1: Check your formulary. Log into your insurance portal and search for "bremelanotide" or "Vyleesi." Note the tier and any prior authorization (PA) requirements.

Step 2: If covered with PA, ask your clinician's office to submit the PA. If denied, request an appeal. The clinician's office can cite the RECONNECT trial data and the ACOG committee opinion on female sexual dysfunction to support medical necessity.

Step 3: If covered but high copay, enroll in the Vyleesi savings card at enrollment. The card applies on top of your insurance and should reduce copay to the program minimum.

Step 4: If not covered or uninsured, apply for the Patient Assistance Program if income-eligible. If income exceeds PAP thresholds, compare:

• Branded Vyleesi at list price with savings card (card applies even without insurance in some program iterations; verify current terms)
• Compounded bremelanotide from an accredited 503A pharmacy via telehealth, paid with HSA/FSA funds

Step 5: Regardless of pathway, document your prescription for HSA/FSA reimbursement.

A woman in the 22% tax bracket using her HSA to pay $120 per compounded dose saves approximately $26 per dose in tax benefits, which adds up to $104 over four doses per year.

Direct Quotations from Guidelines

The FDA Vyleesi prescribing information states: "Vyleesi is contraindicated in patients with cardiovascular disease because of the risk of transient increases in blood pressure and decreases in heart rate."

The Menopause Society 2022 sexual health position statement notes: "Bremelanotide is approved for premenopausal women with HSDD; data in postmenopausal women are insufficient to support a recommendation."

These quotations matter for your conversation with your clinician. If you are postmenopausal, your prescriber is working outside the evidence base. If you have any cardiac history, the drug is not appropriate for you regardless of cost.